---
layout: post
title: "Prospective Grant of an NCI Exclusive Patent License: Use of Anti-Mesothelin Immunotoxins for the Treatment of Mesothelin-Expressing Cancers"
date: 2026-02-04 21:49:17 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-17379
original_published: 2025-09-10 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an NCI Exclusive Patent License: Use of Anti-Mesothelin Immunotoxins for the Treatment of Mesothelin-Expressing Cancers

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** September 10, 2025 00:00 UTC
**Document Number:** 2025-17379

## Summary

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an NCI Exclusive Patent License to practice the inventions embodied in the patents listed in the Supplementary Information section of this notice to Lysin Therapeutics, Inc. (Lysin), a company located in Silver Spring, MD.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/09/10/2025-17379/prospective-grant-of-an-nci-exclusive-patent-license-use-of-anti-mesothelin-immunotoxins-for-the)
- API: https://www.federalregister.gov/api/v1/documents/2025-17379

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
